Related references
Note: Only part of the references are listed.Old dogs, new trick: classic cancer therapies activate cGAS
Seoyun Yum et al.
CELL RESEARCH (2020)
The regulatory network behind MHC class I expression
Marlieke L. M. Jongsma et al.
MOLECULAR IMMUNOLOGY (2019)
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
Seong-Ho Kang et al.
ONCOIMMUNOLOGY (2019)
Defective HLA class I antigen processing machinery in cancer
Lei Cai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Rapid Advances in Immunotherapy to Treat Cancer
Jeannine S. McCune
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Complex pattern of immune evasion in MSI colorectal cancer
Mine Ozcan et al.
ONCOIMMUNOLOGY (2018)
Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer
Stephan Paschke et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
Gillian Dunphy et al.
MOLECULAR CELL (2018)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma
Sherille D. Bradley et al.
ONCOIMMUNOLOGY (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs
Diana Rose E. Ranoa et al.
ONCOTARGET (2016)
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Elliott J. Brea et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Classic and Nonclassic HLA Class I Expression in Penile Cancer and Relation to HPV Status and Clinical Outcome
Rosa S. Djajadiningrat et al.
JOURNAL OF UROLOGY (2015)
Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome
Ingrid M. M. Schellens et al.
PLOS ONE (2015)
Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients
E. C. M. Zeestraten et al.
BRITISH JOURNAL OF CANCER (2014)
Expression of HLA Class I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon Cancer
Marlies S. Reimers et al.
JAMA INTERNAL MEDICINE (2014)
MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
Patrizia Leone et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers
Anurag Singh et al.
CELL (2012)
KRAS Mutation and NF-κB Activation Indicates Tolerance of Chemotherapy and Poor Prognosis in Colorectal Cancer
Gen Lin et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
Shan Wan et al.
PLOS ONE (2012)
Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer
Atsuko Kasajima et al.
HUMAN PATHOLOGY (2010)
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells
Christine Sers et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer:: Specific role of class I histone deacetylases in vitro and in vivo
Wilko Weichert et al.
CLINICAL CANCER RESEARCH (2008)
Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity
Amit A. Lugade et al.
JOURNAL OF IMMUNOLOGY (2008)
Different regulation of MHC Class I antigen processing components in human tumors
Barbara Seliger
JOURNAL OF IMMUNOTOXICOLOGY (2008)
Clinical impact of HLA class I expression in rectal cancer
Frank M. Speetjens et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma
Akash M. Mehta et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
NFS Watson et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
Z Madjd et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?
C Demanet et al.
BLOOD (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)